Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06642792
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-26
Brief Title:
A Study of AK129 With or Without AK117 in PDL1-refractory Classic Hodgkin Lymphoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase III Study of AK129 Bispecific Antibody Targeting LAG-3 and PD-1 Monotherapy or in Combination With AK117 Anti-CD47 Monoclonal Antibody in Relapse or Refractory Classic Hodgkin Lymphoma With PD-1L1 Inhibitor Treatment Failure
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase III study All subjects are patients diagnosed with relapse or refractory RR classic Hodgkin lymphoma cHL and has progressed on treatment with PD-1L1 inhibitor therapy The purpose of this study is to evaluate the safety and efficacy of AK129 bispecific antibody targeting LAG-3 and PD-1 monotherapy or in combination with AK117 anti-CD47 monoclonal antibody in RR cHL with PD-1L1 inhibitor treatment failure
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None